SECONDARY CYTOREDUCTIVE SURGERY IMPROVED OVERALL SURVIVAL VERSUS CHEMOTHERAPY ALONE IN RECURRENT EPITHELIAL OVARIAN CANCER PATIENTS A POPULATION-BASED STUDY

Abstract Background Ovarian cancer is the fifth most common cancer among females in Brunei Darussalam in 2017. This study aims to provide nationwide cancer statistics including cancer incidence, mortality, survival rates for women diagnosed with epithelial ovarian cancer, and evaluate the prognostic factors of epithelial ovarian cancer patients survival in Brunei Darussalam. Methods This is a retrospective population-based study of patients diagnosed with epithelial ovarian cancer between 1st January 2007 and 31st December 2017 in Brunei Darussalam. Crude, age-specific, age-standardized incidence and mortality rates per 100,000 women were calculated. Kaplan-Meier survival analysis method was used to determine the overall 5-years survival rate of epithelial ovarian cancer patients. Log-rank test was used to examine the differences in survival between groups. The Multivariable Cox Proportional Hazard (PH) regression models were used to estimate the hazard ratio (HRs) for overall survival and to identify the prognostic factor of epithelial ovarian cancer patients. PH assumption over time for these models were evaluated. Results A total of 207 patients were included in the study. The crude incidence and mortality rates were 9.7 and 3.6 per 100,000 respectively while the age-standardized incidence and mortality rates were 11.3 (95% CI: 9.7, 12.9) and 4.5 (95% CI: 3.4, 5.6) per 100,000 respectively in the period 2007-2017. The overall mean age at diagnosis was 48.4 (standard deviation=15.3) years. The overall survival rates at 1, 3, and 5 years for epithelial ovarian cancer patients were 79.7%, 69.7%, and 61.4% respectively. Age at diagnosis, district, cancer stage, and histology were the significant prognostic factors for epithelial ovarian cancer patients’ survival. Older age at diagnosis (\(\ge\)70 years vs <40 years), regional or advanced stage (vs localized stage) and having undifferentiated or other epithelial ovarian (vs serous carcinoma) were associated with having higher hazard of death while patients residing in Belait district (vs Brunei Muara) was associated with having lower hazard. Conclusion More efforts and research should be made to detect the disease at early stage through education and public awareness to ensure the availability of high-quality care for all women with ovarian cancer and to improve the survival rates of patients with ovarian cancer.

Download Full-text

Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.01.002 ◽

2009 ◽

Vol 113 (2) ◽

pp. 264-269 ◽

Cited By ~ 69

Author(s):

Hee Seung Kim ◽

Mi-Kyung Kim ◽

Hyun Hoon Chung ◽

Jae Weon Kim ◽

Noh Hyun Park ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Clinical Outcomes ◽

Genetic Polymorphisms ◽

Population Based ◽

Korean Population ◽

Platinum Compounds ◽

Population Based Study

Download Full-text

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study

European Urology Open Science ◽

10.1016/j.euros.2020.12.002 ◽

2021 ◽

Vol 24 ◽

pp. 1-8

Author(s):

Lise H. Omland ◽

Henriette Lindberg ◽

Andreas Carus ◽

Anne Birgitte Als ◽

Niels Viggo Jensen ◽

...

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Real World ◽

Locally Advanced ◽

Population Based ◽

Treatment Patterns ◽

Population Based Study ◽

Tract Cancer

Download Full-text

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.

Journal of Clinical Oncology ◽

10.1200/jco.1998.16.2.397 ◽

1998 ◽

Vol 16 (2) ◽

pp. 397-404 ◽

Cited By ~ 185

Author(s):

O T Jóhannsson ◽

J Ranstam ◽

A Borg ◽

H Olsson

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Matched Control ◽

Brca1 Mutation ◽

Population Based ◽

Control Group ◽

Breast And Ovarian Cancer ◽

Population Based Study ◽

Matched Control Group ◽

Group Survival

PURPOSE Recent studies indicate that BRCA1 breast and ovarian tumors may have an advantageous survival. In this population-based study, the survival of carriers of a mutated BRCA1 gene was investigated. PATIENTS AND METHODS The survival of 71 BRCA1-associated cancer patients (33 breast cancer, seven breast and ovarian cancer, and 31 ovarian cancer patients from 21 families with BRCA1 germline mutations) diagnosed after 1958 was compared with that of a population-based comparison group that consisted of all other invasive breast (n = 28,281) and ovarian (n = 7,011) cancers diagnosed during 1958 to 1995, as well as an age- and stage-matched control group. RESULTS No apparent survival advantage was found for BRCA1-associated breast cancers upon direct comparison. After adjustment for age and calendar year of diagnosis, survival was equal to or worse than that of the comparison group (hazards ratio [HR], 1.5; 95% confidence interval [CI], 0.9 to 2.4). In comparison with an age- and stage-matched control group, survival again appeared equal or worse (HR, 1.5; 95% CI, 0.6 to 3.7). For BRCA1-associated ovarian cancers, an initial survival advantage was noted that disappeared with time. Due to this time dependency, multivariate analyses cannot adequately be analyzed. Compared with the age- and stage-matched control group, survival again appeared equal or worse (HR, 1.2; 95% CI, 0.5 to 2.8). CONCLUSION The results suggest that survival for carriers of a BRCA1 mutation may be similar, or worse than, that for breast and ovarian cancer in general. This finding is in accordance with the adverse histopathologic features observed in BRCA1 tumors and underlines the need for surveillance in families that carry a BRCA1 mutation.

Download Full-text